GlassScriptPhysician profile
Carrie Mosley
NPI 1336190933
$10,928.78
in general payments reported to CMS, 2019-2025
34 companies · $2,322 in 2025
The $2,322 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,902 · 2022: $1,989 · 2023: $2,461 · 2024: $2,255 · 2025: $2,322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,038.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,037.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,064.01 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,663.53 | 2021-2025 | Airsupra, Breztri, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,349.96 | 2021-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Actelion Pharmaceuticals US, INC. | $711.62 | 2021-2024 | Uptravi, Opsumit |
| Genzyme Corporation | $538.93 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $388.00 | 2021-2025 | Winrevair |
| United Therapeutics Corporation | $365.89 | 2021-2025 | Tyvaso, Tyvaso, Orenitram |
| Verona Pharma, INC. | $342.15 | 2025 | Ohtuvayre |
| Grifols USA, LLC | $337.27 | 2021-2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $249.78 | 2024-2025 | Glassia |
| Regeneron Healthcare Solutions, INC. | $239.84 | 2022-2025 | Dupixent |
| Insmed, INC. | $238.40 | 2021-2025 | Arikayce |
| Baxter Healthcare | $234.12 | 2022-2025 | Hillrom - Monarch Airway Clearance System, Hillrom - Life 2000 Ventilation System |
| Electromed, INC. | $197.87 | 2021-2025 | Smartvest |
| Pfizer INC. | $180.58 | 2021-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $159.17 | 2021-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $149.78 | 2022-2025 | |
| Amgen INC. | $105.86 | 2021-2025 | Tezspire |
| Silk Road Medical, INC. | $79.70 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Tactile Systems Technology INC | $36.40 | 2024 | Entre Plus, Flexitouch Plus |
| Viatris Specialty LLC | $36.33 | 2025 | Yupelri |
| Genentech USA, INC. | $30.67 | 2025 | Xolair |
| Advanced Respiratory, INC | $27.75 | 2021 | |
| Optinose US, INC. | $26.28 | 2024 | |
| Lilly USA, LLC | $25.63 | 2021-2024 | Jardiance, Zepbound |
| Alk-Abello, INC | $20.80 | 2024 | Grastek, Odactra, Ragwitek |
| Nabriva Therapeutics, Plc | $19.20 | 2022 | |
| Abbvie INC. | $19.02 | 2022 | |
| Mayne Pharma Commercial LLC | $18.88 | 2022 | |
| Gilead Sciences, INC. | $15.59 | 2025 | |
| Exact Sciences Corporation | $15.56 | 2024 | Cologuard Collection Kit |
| Smith+Nephew, INC. | $14.82 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.68 | 2024 | |
| Janssen Pharmaceuticals, INC | $10.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carrie Mosley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.